SCHEMBL4495654

SCHEMBL4495654

CCC1(C)OC(=O)COC1=O

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34628 0.77 HSD11B1 (0.31)
SCHEMBL887992 0.77
SCHEMBL531260 0.73 LMNA (0.31) LMNA
SCHEMBL16804589 0.70
SCHEMBL29143569 0.68 KDM4E (0.31) KDM4ELMNACYP2C19
SCHEMBL7639189 0.68
SCHEMBL18287715 0.67
Butyrolactone SCHEMBL8984027 0.66 CA1 (0.42) LMNA
SCHEMBL13917985 0.65 KDM4E (0.32) KDM4ELMNACYP2C19
SCHEMBL19663105 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504524-B2 Method for synthesis of 2,5-dioxane-1,4-diones SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 2009-03-17 US disclosed
US-7504524-B2 Method for synthesis of 2,5-dioxane-1,4-diones SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 2009-03-17 US disclosed
US-7504524-B2 Method for synthesis of 2,5-dioxane-1,4-diones SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 2009-03-17 US disclosed
US-20080004453-A1 Method for Synthesis of 2,5-Dioxane-1,4-Diones SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 2008-01-03 US disclosed
US-20080004453-A1 Method for Synthesis of 2,5-Dioxane-1,4-Diones SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 2008-01-03 US disclosed
US-20080004453-A1 Method for Synthesis of 2,5-Dioxane-1,4-Diones SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 2008-01-03 US disclosed
EP-1773803-A1 METHOD FOR THE SYNTHESIS OF 2,5-DIOXANE-1,4-DIONES Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S) SAS (FR) 2007-04-18 EP disclosed
WO-2006018524-A1 METHOD FOR THE SYNTHESIS OF 2,5-DIOXANE-1,4-DIONES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004453-A1 Method for Synthesis of 2,5-Dioxane-1,4-Diones CBR3, CBR1, CYP2W1 KDM4E 1336/4885LMNA 1688/4885CYP2C19 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.